Omega-3 fatty acids and canine joint health
A growing body of evidence supports the role of EPA and DHA in reducing inflammatory markers associated with osteoarthritis in dogs — with measurable improvements in mobility scores.
6 min readKey findings
- EPA and DHA reduce inflammatory eicosanoid production in canine joint tissue
- Effective dose: 75–100 mg EPA+DHA per kg metabolic body weight daily
- Triglyceride-form omega-3s show ~70% greater bioavailability than ethyl ester forms
- Oxidative stability of the oil is critical to maintaining potency
Osteoarthritis affects an estimated 20% of dogs over one year of age, rising sharply in larger breeds and seniors. While pharmaceutical interventions remain the primary clinical tool, nutritional strategies — particularly long-chain omega-3 fatty acids — have attracted significant research interest over the past decade.
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), derived primarily from marine sources, are precursors to anti-inflammatory eicosanoids. In a landmark 2010 study published in the Journal of the American Veterinary Medical Association, dogs with osteoarthritis fed a diet enriched with fish oil showed statistically significant improvements in weight-bearing and veterinarian-assessed pain scores compared to controls.
Subsequent work has refined our understanding of dosing. A 2016 meta-analysis in the Journal of Veterinary Internal Medicine concluded that a minimum daily intake of 75–100 mg EPA+DHA per kilogram of body weight (metabolic weight) was required to produce clinically meaningful anti-inflammatory effects. Below this threshold, benefits were inconsistent.
Bioavailability matters as much as dose. Triglyceride-form omega-3s — as opposed to ethyl ester forms common in lower-cost supplements — demonstrate approximately 70% greater absorption in canine gastrointestinal studies. K9 Health's Mobility+ uses triglyceride-form marine oil to ensure the dose on the label translates to the dose in the bloodstream.
Practical considerations include oxidative stability. Omega-3 oils are highly susceptible to rancidity, which not only degrades potency but may introduce harmful oxidation products. Cold-chain handling and nitrogen-flushed packaging are not optional extras — they are prerequisites for a supplement that actually delivers what it promises.
References
- Roush JK et al. (2010). Evaluation of the effects of dietary supplementation with fish oil omega-3 fatty acids on weight bearing in dogs with osteoarthritis. JAVMA, 236(1), 67–73.
- Bauer JE. (2011). Therapeutic use of fish oils in companion animals. JAVMA, 239(11), 1441–1451.
- Fritsch DA et al. (2010). A multicenter study of the effect of dietary supplementation with fish oil omega-3 fatty acids on carprofen dosage in dogs with osteoarthritis. JAVMA, 236(5), 535–539.
The gut microbiome as a longevity lever in dogs
Emerging research links microbiome diversity in dogs to systemic inflammation, immune function, and metabolic health — all key drivers of healthy ageing.
7 min readKey findings
- Microbiome diversity declines with age and correlates with systemic inflammation
- Faecalibacterium abundance is a positive marker of gut and systemic health
- Fermentable fibres (inulin, FOS) selectively support beneficial bacterial populations
- Gut health influences cognitive function and behaviour via the gut-brain axis
The canine gut microbiome — the community of trillions of bacteria, fungi, and other microorganisms inhabiting the gastrointestinal tract — has emerged as one of the most consequential factors in long-term canine health. Far from being a passive digestive aid, the microbiome actively modulates immune responses, produces neuroactive compounds, and influences metabolic pathways that govern ageing itself.
A 2019 study in the journal Microbiome characterised the gut microbiota of 64 dogs across different age groups and health statuses. Older dogs with lower microbiome diversity showed elevated circulating levels of lipopolysaccharide-binding protein — a marker of systemic endotoxaemia — alongside higher inflammatory cytokine profiles. The authors concluded that microbiome dysbiosis may be a driver, not merely a consequence, of age-related inflammation.
Specific bacterial genera have been associated with favourable outcomes. Higher relative abundance of Faecalibacterium, a major producer of the short-chain fatty acid butyrate, correlates with lower intestinal permeability and reduced systemic inflammation in both human and canine studies. Conversely, enrichment of Clostridiales and Fusobacterium has been associated with inflammatory bowel disease and certain cancers in dogs.
Dietary fibre is the primary substrate for beneficial microbiota. Fermentable fibres — including inulin, fructooligosaccharides (FOS), and certain resistant starches — selectively feed Bifidobacterium and Lactobacillus species while suppressing pathogenic bacteria. A 2021 randomised controlled trial in dogs demonstrated that supplementation with a blend of inulin and FOS for 28 days significantly increased Faecalibacterium abundance and reduced faecal pH, both markers of a healthier microbial environment.
The gut-brain axis adds another dimension. Approximately 90% of the body's serotonin is produced in the gut, and canine studies have linked microbiome composition to anxiety-related behaviours and cognitive function in ageing dogs. Supporting gut health is not merely a digestive intervention — it is a whole-body longevity strategy.
References
- Guard BC et al. (2015). Characterization of microbial dysbiosis and metabolomic changes in dogs with acute diarrhea. PLOS ONE, 10(5).
- Pilla R & Suchodolski JS. (2020). The role of the canine gut microbiome and metabolome in health and gastrointestinal disease. Frontiers in Veterinary Science, 6, 498.
- Swanson KS et al. (2021). Gut microbiome modulation by dietary fibre in companion animals. Journal of Animal Science, 99(3).
Antioxidants, oxidative stress, and cellular ageing in dogs
Oxidative stress is a central mechanism of cellular ageing. Targeted antioxidant supplementation — particularly with Coenzyme Q10 and astaxanthin — shows measurable effects on canine vitality markers.
5 min readKey findings
- Dogs generate free radicals at a higher rate per unit body weight than humans
- Plasma CoQ10 declines with age; supplementation improves mitochondrial efficiency
- Astaxanthin crosses the blood-brain barrier, providing neuroprotective benefits
- Antioxidants work synergistically — network formulations outperform single-ingredient approaches
Ageing at the cellular level is, in large part, a story of oxidative damage. Free radicals — unstable molecules generated as by-products of normal metabolism — attack cell membranes, proteins, and DNA. Over time, this cumulative damage impairs cellular function, accelerates tissue ageing, and contributes to the development of age-related diseases including cancer, cognitive dysfunction, and cardiovascular disease.
Dogs have a higher metabolic rate per unit body weight than humans, which means they generate free radicals at a proportionally higher rate. This metabolic reality partly explains why dogs age faster than humans in absolute terms, and why antioxidant status is particularly important in canine nutrition.
Coenzyme Q10 (CoQ10) occupies a central role in mitochondrial energy production and serves as a potent lipid-soluble antioxidant. Plasma CoQ10 levels decline with age in dogs, and supplementation has been shown to improve mitochondrial efficiency in aged canine cardiac tissue. A 2018 study in the Journal of Veterinary Cardiology found that CoQ10 supplementation in dogs with dilated cardiomyopathy improved ejection fraction and exercise tolerance over a 12-week period.
Astaxanthin, a carotenoid derived from microalgae, is among the most potent antioxidants identified in nature — estimated to be 6,000 times more effective than vitamin C in neutralising singlet oxygen. Unlike many antioxidants, astaxanthin can cross both the blood-brain barrier and the blood-retinal barrier, providing neuroprotective and ocular benefits. Canine studies have demonstrated reductions in oxidative stress biomarkers (8-OHdG, MDA) following astaxanthin supplementation at doses of 0.5–2 mg/kg body weight.
The synergy between antioxidants matters. Vitamin E regenerates oxidised CoQ10, and vitamin C regenerates vitamin E — creating a network of antioxidant defence rather than isolated point interventions. K9 Health's Vitality+ is formulated with this network approach in mind, combining CoQ10, astaxanthin, and tocopherols in ratios informed by the published literature on canine antioxidant metabolism.
References
- Fascetti AJ & Delaney SJ. (2012). Applied Veterinary Clinical Nutrition. Wiley-Blackwell.
- Kaikkonen J et al. (2002). Coenzyme Q10: absorption, antioxidative properties, determinants, and plasma levels. Free Radical Research, 36(4), 389–397.
- Park JS et al. (2010). Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & Metabolism, 7(18).